PazopanibMeSH Supplementary Concept

https://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-VEGFR-axitinib-cabozantinib-pazopanib-sorafenib-sunitinib
2019
false
false
false
France
Axitinib
cabozantinib
pazopanib
Sorafenib
Sunitinib
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
risk factors
patient education as topic
continuity of patient care
administration, oral
receptors, vascular endothelial growth factor
carcinoma, renal cell
drug interactions
pregnancy
Tyrosine Kinase Inhibitors
guidelines for drug use
Sorafenib
pazopanib
Axitinib
Sunitinib
cabozantinib
pyrimidines
sulfonamides
anilides
pyridines
pyrimidines
sulfonamides
anilides
pyridines
anilides
pyridines
pyrimidines
sulfonamides

---
https://www.has-sante.fr/jcms/p_3118709/fr/votrient
2019
false
false
false
France
pazopanib
adult
carcinoma, renal cell
sarcoma
Soft Tissue Sarcoma
protein kinase inhibitors
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
pazopanib
pyrimidines
sulfonamides

---
https://www.has-sante.fr/jcms/p_3103874/fr/votrient
2019
false
false
false
France
sarcoma
Soft Tissue Sarcoma
treatment outcome
survival analysis
pazopanib
protein kinase inhibitors
protein-tyrosine kinases
adult
pazopanib
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
pazopanib
pyrimidines
sulfonamides
pyrimidines
sulfonamides

---
http://www.has-sante.fr/portail/jcms/c_2560232/fr/votrient
http://www.has-sante.fr/portail/jcms/c_1623661/fr/votrient
http://www.has-sante.fr/portail/jcms/c_2560232/fr/votrient-pazopanib-inhibiteur-de-tyrosine-kinase
2015
false
France
French
Advanced Malignant Neoplasm
protein kinase inhibitors
protein-tyrosine kinases
guidelines for drug use
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
pazopanib
administration, oral
pazopanib
treatment outcome
survival analysis
neoplasm staging
randomized controlled trials as topic
carcinoma, renal cell
pyrimidines
sulfonamides

---
http://www.meddispar.fr/Medicaments/VOTRIENT-200-B-30/(type)/letter/(value)/V/(cip)/3400949131341
2014
false
false
false
drug information
administration, oral
drug prescriptions
legislation, drug
pazopanib
pazopanib
continuity of patient care
pyrimidines
sulfonamides

---
http://www.meddispar.fr/Medicaments/VOTRIENT-400-B-30/(type)/letter/(value)/V/(cip)/3400949131570
http://www.meddispar.fr/Medicaments/VOTRIENT-400-B-60/%28type%29/letter/%28value%29/V/%28cip%29/3400949131631
2014
false
false
false
drug information
administration, oral
drug prescriptions
legislation, drug
continuity of patient care
pazopanib
pazopanib
pyrimidines
sulfonamides

---
http://www.has-sante.fr/portail/jcms/c_1359730/votrient
http://www.has-sante.fr/portail/upload/docs/evamed/CT-12478_VOTRIENT%20Sarcomes_Avis2_CT12478.pdf
2013
false
France
French
evaluation of the transparency committee
pazopanib
administration, oral
insurance, health, reimbursement
adult
sarcoma
neoplasm metastasis
treatment outcome
survival analysis
clinical trials as topic
antineoplastic agents
protein kinase inhibitors
pyrimidines
sulfonamides
pazopanib

---
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/34855a-fra.php
2013
false
Canada
French
English
Tyrosine Kinase Inhibitors
pharmacovigilance note
pazopanib
pazopanib
continuity of patient care
Chemical and Drug Induced Liver Injury
Chemical and Drug Induced Liver Injury
Chemical and Drug Induced Liver Injury
drug monitoring
bilirubin
protein kinase inhibitors
protein-tyrosine kinases
guidelines for drug use
hyperbilirubinemia
administration, oral
pyrimidines
sulfonamides

---
https://www.ema.europa.eu/medicines/human/EPAR/Votrient
2012
false
United Kingdom
French
English
summary of product characteristics
package leaflet
drug evaluation
syndication feed
pazopanib
pazopanib
pazopanib
pyrimidines
pyrimidines
sulfonamides
sulfonamides
treatment outcome
drug approval
administration, oral
carcinoma, renal cell
protein kinase inhibitors
protein kinase inhibitors
antineoplastic agents
antineoplastic agents
adult
aged
drug interactions
pregnancy
breast feeding
fertility
drug evaluation, preclinical
pyrimidines
sulfonamides
sarcoma

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=63803884
2012
France
summary of product characteristics
package leaflet
tablets
pazopanib

---
http://agence-prd.ansm.sante.fr/php/ecodex/extrait.php?specid=62894653
2012
France
summary of product characteristics
package leaflet
pazopanib
tablets

---
http://www.has-sante.fr/portail/jcms/c_1024751/votrient
http://www.has-sante.fr/portail/jcms/c_1069337/votrient-pazopanib-inhibiteur-de-tyrosine-kinase-synthese-d-avis
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-03/votrient_-_ct-_8713.pdf
2011
false
France
French
evaluation of the transparency committee
guidelines for drug use
Tyrosine Kinase Inhibitors
pyrimidines
sulfonamides
administration, oral
pazopanib
pazopanib
orphan drug production
insurance, health, reimbursement
kidney neoplasms
protein kinase inhibitors
treatment outcome
protein-tyrosine kinases

---
http://www.oncoprof.net/Generale2000/g11_AutresTraitements/g11_at10e.php
2011
false
true
false
France
receptors, vascular endothelial growth factor
pyrimidines
pyrimidines
pyrimidines
pyrimidines
sulfonamides
sulfonamides
sulfonamides
sulfonamides
Tyrosine Kinase Inhibitors
pazopanib

---